Orphazyme Annual Report 2018 Presentation

Copenhagen, DENMARK


Orphazyme A/S
Investor news                                                                                                                                     

No. 01/2019                                                                                                                                        
Company Registration No. 32266355                                                                                                                                                                           


Copenhagen, Denmark, February 25, 2019 – Orphazyme A/S (ticker: ORPHA.CO), a biopharmaceutical company dedicated to developing treatments for patients living with rare diseases, today announced that the Company will be hosting an investor call at which Chief Executive Officer, Anders Hinsby, and Chief Financial Officer, Anders Vadsholt, will be presenting the Orphazyme Annual Report 2018. The presentation will be followed by a Q&A session.

The call will be held on Friday, March 1, 2019 at 11.00 AM CET.

Dial-in details:

  • Denmark: +45 32 72 80 42
  • France: +33 (0) 176 700 794
  • Netherlands: +31 (0) 207 143 545
  • Sweden: +46 (0) 850 692 180
  • United Kingdom: +44 (0) 844 571 88 92
  • United States: +1 63 15 107 495

Event Title: Orphazyme Annual Report 2018

Confirmation code: 1127327

The presentation will also be available via webcast: https://edge.media-server.com/m6/p/et2opupq

After the call, the presentation will be available via the above link or by using the following dial-in details:

  • International: +44 (0) 3333009785
  • Confirmation code: 1127327


For additional information, please contact

Orphazyme A/S
Anders Vadsholt, CFO                         +45 28 98 90 55


About Orphazyme A/S 
Orphazyme is a biopharmaceutical company focused on bringing novel treatments to patients living with life-threatening or debilitating rare diseases. Our research focuses on developing therapies for diseases caused by misfolding of proteins and lysosomal dysfunction. Arimoclomol, the company’s lead candidate, is in clinical development for four orphan diseases: Niemann-Pick disease Type C, Gaucher disease, sporadic Inclusion Body Myositis, and Amyotrophic Lateral Sclerosis. The Denmark-based company is listed on Nasdaq Copenhagen (ORPHA.CO). For more information, please visit www.orphazyme.com

Forward-looking statement
This press release may contain certain forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, all statements other than statements of historical fact included in this press release about future events are subject to (i) change without notice and (ii) factors beyond the Company’s control. These statements may include, without limitation, any statements preceded by, followed by or including words such as “target,” “believe,” “expect,” “aim,” “intend,” “may,” “anticipate,” “estimate,” “plan,” “project,” “will,” “can have,” “likely,” “should,” “would,” “could” and other words and terms of similar meaning or the negative thereof. Forward-looking statements are subject to inherent risks and uncertainties beyond the Company’s control that could cause the Company’s actual results, performance or achievements to be materially different from the expected results, performance or achievements expressed or implied by such forward-looking statements. Except as required by law, the Company assumes no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in the forward-looking statements, even if new information becomes available in the future.

Attachment


Attachments

01-2019 Orphazyme Annual Report 2018 Presentation